biomind.ai: Advancing Healthcare with AI-Powered Medical Imaging Analysis

biomind.ai is a cutting-edge, ISO 13485:2016 certified healthcare AI company delivering diagnostic support software systems that leverage deep learning and machine learning to enhance medical imaging analysis across multiple specialties. Designed to assist physicians in accurate and rapid diagnosis, the platform supports clinical decision-making in neurology, cardiology, pulmonology, and breast imaging, with tools for automated lesion segmentation, quantitative analysis, and risk assessment. Trusted by hospitals globally and approved by major regulatory bodies including NMPA, CE, and Singapore HSA, biomind.ai stands at the forefront of AI in healthcare with proven performance in conditions like stroke, lung diseases, heart MRI, and brain tumors. Its systems reduce observer variability, accelerate workflows, and enable data-driven insights for both clinical and research applications.

Key Features:

• AI-Powered Medical Imaging Analysis: Deep learning models for CT, MRI, and angiography across 12 medical domains.
• Lung CT Diagnostic Support: Automated detection and analysis of lung nodules, tuberculosis, and pneumonia.
• Breast MRI Diagnostic Support: Lesion segmentation, BI-RADS classification, and anatomical analysis.
• Intracranial Tumor Diagnosis: AI-aided identification and classification of 16 types of brain tumors.
• Cerebral Small Vessel Disease (CSVD) Detection: Fast, accurate segmentation of white matter hyperintensities in under 15 seconds.
• Intracerebral Hemorrhage Risk Assessment: Predicts early hematoma expansion using non-contrast CT with high accuracy.
• AIS Penumbra Analysis: Quantifies tissue perfusion parameters (CBV, CBF, MTT, Tmax) for stroke treatment planning.
• Heart MRI Quantitative Analysis: Evaluates ejection fraction, cardiac volumes, filling/emptying rates, and LV wall movement.
• CTA/MRA Vascular Analysis: 3D reconstruction and detection of stenosis and plaque in cerebral vessels.
• CT Perfusion (CTP) & MR Perfusion (PWI) Evaluation: Automated assessment of infarction, hypoperfusion, and penumbra regions.
• Multimodal 3D Fusion Reconstruction: Integrates data from multiple imaging sources for comprehensive visualization.
• Structured Report Generation: Automatically identifies imaging modality and generates clinical reports based on arterial territories.
• Targeted Genome Data Mining: AI-driven platform for clinical diagnosis and drug development using multi-omics data.
• Drug Screening Platform: Accelerates pharmaceutical R&D through AI-powered analysis.
• iStroke Tool (Launched 2021): Intelligent decision support for acute ischemic stroke treatment.
• High Clinical Accuracy: Models achieve DSC values of 0.94 (segmentation) and 0.92–0.96 (classification) on large-scale datasets.
• Regulatory Approvals: First medical device to receive NMPA (China FDA), Singapore HSA, CE, and other international accreditations.
• Global Deployment: Used in 6 hospitals in China since 2020 for COVID-19 diagnosis with PCR validation.
• Research & Clinical Integration: Offers both clinical-grade and research-use-only tools with collaboration with leading research institutes.

Pricing: biomind.ai offers a freemium model, providing access to research-use tools and premium clinical solutions through subscription-based licensing for healthcare institutions.

Conclusion: biomind.ai is a transformative force in healthcare AI, delivering precision, speed, and reliability across critical diagnostic domains—making it an indispensable ally for medical professionals striving for better patient outcomes worldwide.